December 27, 2021
December 27, 2021 – Padagis US LLC has recalled three lots of nitroglycerin lingual spray due to a possible defect in the delivery system. Nitroglycerin lingual spray is indicated for
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Pharmacy Benefits Management
December 27, 2021
December 27, 2021 – Taro Pharmaceuticals has recalled one lot of Clobetasol Propionate Ointment USP, 0.05%, after identifying the presence of Ralstonia pickettii bacteria through
December 27, 2021
December 27, 2021 – Rexulti® (brexpiprazole – Otsuka Pharmaceutical) is now approved to treat schizophrenia in patients who are at least 13 years old. Previously, FDA approval
December 23, 2021
December 23, 2021 – Tascenso ODTTM (fingolimod) orally disintegrating tablets have been approved to treat relapsing forms of multiple sclerosis (MS) in pediatric patients who
December 22, 2021
December 22, 2021 – The U.S. FDA has approved a new indication for Cosentyx® (secukinumab – Novartis)
to treat active enthesitis-related arthritis (ERA) in individuals who are at least
December 22, 2021
December 22, 2021 – Leqvio® (inclisiran) is now FDA approved for use as an adjunct to diet and maximally
tolerated statin therapy to treat adults who have heterozygous familial
December 20, 2021
December 20, 2021 – Caplyta® (lumateperone – Intra-Cellular Therapies) oral capsules are now approved to treat depressive episodes associated with bipolar I or II disorder (bipolar
December 20, 2021
December 20, 2021 – Vocabria® (cabotegravir – ViiV Healthcare) tablets have been approved for use in at-risk adults and adolescents weighing at least 35kg (77 pounds) for short-term